Metraipolis › archive › dc_aa3c4ad949ff
Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability — Europe PMC PMID:41745185
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41745185
- DOI
- 10.3390/nano16040268
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T16:28:34.238Z
- SHA-256 of the archived text
bf6f6f36f78e09d2f3ea361d44254a065e9d0a66f0bebcf9e71457c443c9ed89- Stable URL of this page
https://metraipolis.com/documento/dc_aa3c4ad949ff
How to cite
Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability — Europe PMC PMID:41745185 — Europe PMC (en), https://europepmc.org/article/MED/41745185 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_aa3c4ad949ff (Metraipolis archive dc_aa3c4ad949ff, sha256 bf6f6f36f78e09d2f3ea361d44254a065e9d0a66f0bebcf9e71457c443c9ed89)
BibTeX
@misc{dcaa3c4ad949ff,
title = {Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability — Europe PMC PMID:41745185},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41745185},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_aa3c4ad949ff; sha256 bf6f6f36f78e09d2f3ea361d44254a065e9d0a66f0bebcf9e71457c443c9ed89},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41745185. Agents can read the archived copy with the MCP tool read_document.